News

Biogen announced that it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for talazoparib. The…
Read More...

Chimerix announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox. Chimerix has been working…
Read More...

Ironwood Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to olinciguat (IW-1701) for the treatment of patients with sickle…
Read More...

BlackThorn Therapeutics announced enrollment of the first healthy volunteers in a Phase 1 study of BTRX-335140, a kappa opioid receptor (KOR) antagonist that targets brain circuits that…
Read More...

Chugai Pharmaceutical announced that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for…
Read More...

Hookipa Biotech AG and Gilead Science announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT and…
Read More...

InflaRx, a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate…
Read More...

Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...

Virpax Pharmaceuticals signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. The first investigational…
Read More...

Mylan and Biocon announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed…
Read More...

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell…
Read More...

Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...

Roche announced that the European Commission (EC) has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for…
Read More...

Alcami Corporation announced that it has reached an agreement to be acquired by Madison Dearborn Partners. MDP will acquire a majority ownership position in Alcami from existing…
Read More...

Pharmaceutical Product Development (PPD) and NeoGenomics Laboratories are forming a strategic alliance to provide a seamless and fully integrated global pathology and molecular testing…
Read More...

FORMA Therapeutics and HitGen announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded libraries (DELs). Through this collaborative…
Read More...

Aptar Pharma announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The digital medicine…
Read More...

Daiichi Sankyo Company announced the launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development (hereafter, the consortium) to research and discover drugs for…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta…
Read More...